Welcome to Nimenrix

Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neiserria meningitidis serogroups A, C, W135 and Y1

References

1. Nimenrix. Summary of Product Characteristics, United Kingdom, Pfizer Ltd. Available here.

Prescribing Information
Nimenrix™ prescribing information.

 

< Back to Vaccines Hub

 

PP-NIM-GBR-0218.  June 2020